Outcomes of Radiotherapy in the First-Line Treatment of Recurrent/Metastatic Cervical Cancer: A Multicenter, Retrospective Study

被引：0
|
作者：
Peng, C. [1 ]
Li, X. [1 ]
Tang, W. [1 ]
Guo, Q. [1 ]
Wu, Q. [1 ]
Xie, P. [1 ]
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1086
引用
收藏
页码：S189 / S189
页数：1
相关论文
共 50 条
  • [1] The Safety and Efficacy of Cadonilimab in the First-Line Treatment of Recurrent or Metastatic Cervical Cancer: A Retrospective, Real-World Study
    Jin, G.
    Wang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E693 - E693
  • [2] Real-world outcomes of first-line maintenance therapy for recurrent or metastatic cervical cancer: A multi-center retrospective study
    Peng, Chen
    Li, Xiaolin
    Tang, Wenjie
    Zhu, Wanqi
    Yan, Peile
    Chen, Jinlong
    Zhang, Xueliang
    Guo, Qiufen
    Wu, Qian
    Wang, Qian
    Liu, Naifu
    Ma, Anqun
    Lu, Yuanyuan
    Lv, Pengzhong
    Liu, Jing
    Xie, Peng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 129
  • [3] Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study
    Xia, Xiaoping
    Jiang, Wenjing
    Qi, Wencai
    Hong, Baoli
    Zhao, Weidong
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (12) : 649 - 654
  • [4] Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study
    Cabart, Mathilde
    Frenel, Jean-Sebastien
    Campion, Loic
    Ramee, Jean-Francois
    Dupuis, Olivier
    Senellart, Helene
    Douillard, Jean-Yves
    Bennouna, Jaafar
    CLINICAL COLORECTAL CANCER, 2016, 15 (04) : E165 - E174
  • [5] The metastatic receptor status impact on first-line treatment plans and clinical outcomes for recurrent metastatic breast cancer
    Pannell, T.
    CLINICAL & EXPERIMENTAL METASTASIS, 2019, 36 (02) : 150 - 151
  • [6] THE METASTATIC RECEPTOR STATUS IMPACT ON FIRST-LINE TREATMENT PLANS AND CLINICAL OUTCOMES FOR RECURRENT METASTATIC BREAST CANCER
    Pannell, Allen
    BREAST, 2019, 48 : S47 - S48
  • [7] COST EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN GREECE
    Yfantopoulos, N.
    Gountas, I
    Swami, S.
    Skroumpelos, A.
    Karokis, A.
    VALUE IN HEALTH, 2023, 26 (12) : S62 - S62
  • [8] Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer
    Chitapanarux, I
    Tonusin, A
    Sukthomya, V
    Charuchinda, C
    Pukanhapan, N
    Lorvidhaya, V
    GYNECOLOGIC ONCOLOGY, 2003, 89 (03) : 402 - 407
  • [9] A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy
    Yang, Hui
    Sun, Shaoxing
    Mei, Zijie
    Xiang, Qingming
    Yang, Chunxu
    Chen, Min
    Xie, Conghua
    Zhou, Yunfeng
    Qiu, Hui
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 4665 - 4674
  • [10] Efficacy of pertuzumab in combination with trastuzumab and a taxane in first-line treatment for metastatic breast cancer (MBC): A multicenter, retrospective, observational study
    Gamucci, Teresa
    Mentuccia, Lucia
    Sperduti, Isabella
    Gelibter, Alain
    D'Onofrio, Loretta
    Cassano, Alessandra
    Iezzi, Laura
    Botticelli, Andrea
    Pizzuti, Laura
    Moscetti, Luca
    Barchiesi, Giacomo
    Scinto, Fedele
    Carbognin, Luisa
    Cursano, Maria Concetta
    Foglietta, Jennifer
    Rossi, Ernesto
    Barni, Sandro
    Graziano, Vincenzo
    Magnolfi, Emanuela
    Vici, Patrizia
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345